Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data

Kezar Life Sciences, Inc.

2022-Q2 EPS reported -$0.52

Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.
Cash, cash equivalents and marketable securities totaled $306.8M as of June 30, 2022 (up from $208.4M year-end 2021).
Net loss for Q2 2022 was $16.2M ($0.25 per share) vs $13.0M in Q2 2021.
Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer in July 2022.
R&D expenses $11.3M (+$2.0M YoY); G&A $5.0M (+$1.3M YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.